1. Xeris granted 382,975 restricted stock units to 40 new employees. 2. The awards come under Xeris' Inducement Equity Plan. 3. The restricted stock units will vest over three years. 4. Xeris aims to improve patient lives through innovative therapies. 5. Xeris has a promising pipeline including XP-8121 in Phase 3.
Offering equity awards can attract top talent, enhancing innovation and growth. Historical examples suggest companies often see stock appreciation post such grants, increasing investor confidence.
The stock unit grant signifies strategic growth initiatives, influencing investor sentiment favorably. Such developments can signal to the market Xeris' commitment to future success.
Talent acquisition impacts company longevity and product development. For instance, strong hires can lead to successful pipeline advancements over time, boosting future earnings potential.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2025, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 382,975 shares of its common stock to 40 new employee(s) under Xeris' Inducement Equity Plan.
Xeris' Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The restricted stock units will vest over a period of three years in equal annual installments, and are subject to the employees' continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of Xeris' Inducement Equity Plan and forms of award agreements covering the grants.
About Xeris
Xeris (NASDAQ:XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing's syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and a gastrointestinal motility inhibitor when used as a diagnostic aid; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as early-stage programs leveraging Xeris' technology platforms, XeriSol® and XeriJect®, for its partners.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251003066767/en/
Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com